// App-Quantinova.ai

BSH2020‐PO‐122 : Real‐world outcomes of daratumumab monotherapy in relapsed/refractory myeloma

Researchers

Presenter

  • N. Maouche

Principal Investigators

  • H. Leary

  • F. Collings

  • B. Tseu

  • F. Djebbari

  • G. Vallance

  • K. Ramasamy

  • J. Kothari

Medical Centers

  • Dept of Haematology, Oxford University Hospitals NHS Foundation Trust

  • Department of Haematology, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes

  • Haematology, Great Western Hospital Foundation Trust, Swindon

  • Department of Haematology, Buckinghamshire Healthcare NHS Trust, Bucks

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Infective endocarditis

  • Sepsis

Biomarkers

  • Cluster of Differentiation 38

  • Cluster of differentiation 79A

  • Immunoglobulin G

Drug/Treatment

  • Lenalidomide

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved